When is a Conference Presentation NOT Really a Conference Presentation? (NWBO)

Today is the big day. 4 June 2022. The date the retail cult around decades old bioturd, and current John M. Fife plaything, Northwest Biotherapeutics (NWBO) believe the company is “presenting” their “successful” Phase 3 data for their utterly useless dendritic cell vaccine for brain cancer (DC-Vax) at the American Society of Clinical Oncology (ASCO) Conference in Chicago.

Of course, just like all of their previously hyped appearances there is much less here than meets the eye.

Deluded longs, fed by social media scoundrels and relentless promotional campaigns, might believe NWBO is giving a legitimate presentation at the conference, invited because of scientific merit. However the reality is that Northwest Bio is not presenting at ASCO per se, rather the company is participating in something called the “Industry Expert Theater.”

So instead of being in the main hall, Northwest is shilling its wares (namely its share certs) back by the food court. The presentation is unofficial, unendorsed, and unaccredited. But what it IS, is bought-and-paid for advertorial nonsense. Unlike legitimate presentations where the speakers are invited by the organizers to share legitimate scientific breakthroughs and engage in legitimate scientific debate, IET presentations are bought and paid for bullshit. How much does it cost to hype your bullshit cancer quackery at ASCO?

Just $95,000 and you too can “present” at ASCO, just like NWBO! What a great use of stock promotion budget. One can read more about the IET here.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

2 comments

  1. Kenny Lay (from below) and Jeffrey Skilling give an approving nod to their former mentee for this level of clever grifting, as they themselves were too obvious back in the day and got caught.

  2. NWBO didn’t do a press release or post the TLD on their website after the NYAS TLD presentation. They know this spun trial data is not going to be popular with the FDA and then the SEC if they start touting it. But yet the paid stock touters are all over it. Going to be ugly.

Leave a Reply to HyGro Cancel reply